Search | Clinical Trials Finder

Conditions: Infant, Newborn, Respiratory Distress Syndrome, Respiratory Insufficiency
Interventions: Early surfactant, Standard practice; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 12 Hours
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Congenital Heart Disease, Hypoplastic Left Heart Syndrome
Interventions: Curosurf, Sham; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 1 Day to 12 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions: Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 3 Days to 10 Days
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: COVID-19, Undefined
Interventions: AT-100; Biological
Lead sponsor: Airway Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions: budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 48 Hours
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more

Conditions: Bronchopulmonary Dysplasia (BPD)
Interventions: Budesonide in Calfactant; Drug
Lead sponsor: Cynthia McEvoy; Other
Eligibility: 3 Days to 14 Days
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Dermatitis
Interventions: PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%, Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%, Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%, Silwet* DA-63 (Momentive) 1.5%, Sodium lauryl sulfate (Sigma Aldrich) 1.0%, Water (control); Other
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Respiratory Distress Syndrome (Neonatal), Surfactant Deficiency Syndrome Neonatal
Interventions: Video Laryngoscopy, Direct Laryngoscopy; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 3 Days
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Neer Infrared Spectroscopy; Device
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 1 Hour to 24 Hours
Enrollment: 50 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions: Calfactant, Budesonide; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Days to 14 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
Interventions: Non-marketed Cosmetic Facial Cleanser; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Bronchopulmonary Dysplasia
Interventions: Infasurf, Pulmicort, Sham; Drug · Other
Lead sponsor: East Carolina University; Other
Eligibility: 24 Weeks to 28 Weeks
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Exosurf, Survanta; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 6 Hours
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 1992
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Endotracheal tube insertion, Laryngeal mask airway insertion; Device
Lead sponsor: Albany Medical College; Other
Eligibility: 4 Hours to 48 Hours
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Albany, New York

Conditions: Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
Interventions: Echography-guided Surfactant THERapy (ESTHER); Diagnostic Test
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Extreme Prematurity, Respiratory Distress Syndrome
Interventions: LISA; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Minutes to 20 Minutes
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neonatal Respiratory Distress Related Conditions, Meconium, Perinatal Morbidity, Neonatal Acidosis, Cord Blood, Neonatal Brain Injury, Maternal Morbidity, Mechanical Ventilation, CPAP, Surfactant, Perinatal Death, Amnioinfusion, NICU Admission
Interventions: Intrauterine pressure catheter, Standard obstetric care at discretion of delivery provider; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Continuous Positive Airway Pressure
Interventions: CPAP/PEEP, Standard management practices; Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 10 Minutes
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 3 more

Conditions: Burns
Interventions: Surfactant Gel; Device
Lead sponsor: Medline Industries; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Maywood, Illinois • Baton Rouge, Louisiana

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: CHF5633, Poractant alfa; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 1 Hour to 24 Hours
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Orange, California + 20 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: CUROSURF® (poractant alfa); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease
Interventions: surfactant airway device; Combination Product
Lead sponsor: ONY; Industry
Eligibility: 24 Weeks and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: San Diego, California • St. Petersburg, Florida • Buffalo, New York + 1 more

Conditions: Respiratory Distress Syndrome (Neonatal), Surfactant
Interventions: Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA), Continuous Positive Airway Pressure (CPAP); Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: 33 Weeks to 38 Weeks
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Chula Vista, California • La Mesa, California • San Diego, California

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

The Budesonide in Babies (BiB) Trial

Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial

A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants

Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

Little Lungs Study

A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants

Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

LISA in the Delivery Room for Extremely Preterm Infants

Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure

Delivery Room CPAP in Extremely Low Birth Weight Infants

Evaluating the Use of a Concentrated Surfactant Gel in Burn Patients

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

Premedication for Less Invasive Surfactant Administration Study (PRELISA)